CXCL10 and lobular neoplasia: Defining improved noninvasive diagnostics and novel therapeutic targets for lupus nephritis (LN) will facilitate better disease management, and studies have implicated interferon (IFN)-γ-induced protein 10 (IP-10) as a candidate serum and urine marker for autoimmune activity and LN in SLE patients [9,10,11,12,13].